Tilray Inc. ($TLRY) Stock Forecast: Down 5.4% Today

What is Tilray Inc.?

Tilray Brands, Inc. (TLRY) operates in the alcohol beverage and medical cannabis sectors and faced a strong bearish movement in the market recently.

Why is Tilray Inc. going down?

TLRY stock is down 5.4% on Mar 20, 2026 16:25

• Acquired BrewDog's US assets to expand alcohol beverage portfolio did not have a positive impact on stock price.
• Despite expanding medical cannabis portfolio in Australia, introducing new products did not prevent bearish trend.
• Underperformance compared to broader market and sector, along with anticipation of negative earnings per share in upcoming report, likely led to bearish movement.
• Consecutive days of losses amidst challenging trading session for overall market emphasized bearish sentiment surrounding the stock.

TLRY Price Chart

TLRY Technical Analysis

TLRY News

Tilray Brands acquires BrewDog’s US assets

Tilray Brands has acquired the US assets of Scottish craft brewer BrewDog. This acquisition expands Tilray's alcohol beverage portfolio, adding new brands and production capabilities in the US market. The strategic move aims to strengthen Tilray's position in the craft beer and spirits sector.

https://www.msn.com/en-us/money/companies/tilray-brands-acquires-brewdog-s-us-assets/ar-AA1YJQWf

Tilray Brands, Inc. (TLRY) Dips More Than Broader Market: What You Should Know

Tilray Brands, Inc. (TLRY) closed down 1.04% at $6.66, underperforming the broader market's daily losses. The company's shares have declined 11.21% over the past month, trailing the Medical sector and the S&P 500. Investors are anticipating Tilray's upcoming earnings report, where analysts project earnings of -$0.14 per share and revenue of $205.93 million, along with full-year estimates of -$0.56 per share and $871.99 million.

https://sg.finance.yahoo.com/news/tilray-brands-inc-tlry-dips-220006450.html

Tilray Brands, Inc. (TLRY) Dips More Than Broader Market: What You Should Know

Tilray Brands, Inc. (TLRY) shares recently dipped by 1.04%, underperforming the broader S&P 500. Over the last month, the company's shares have decreased by 11.21%, also lagging behind its sector. Analysts anticipate Tilray to report earnings of -$0.14 per share and revenue of $205.93 million in its upcoming earnings report, with further projections for the fiscal year.

https://finance.yahoo.com/markets/stocks/articles/tilray-brands-inc-tlry-dips-220006450.html

Tilray Brands Inc. stock falls Thursday, underperforms market

Tilray Brands Inc. (TLRY) shares decreased by 1.04% to $6.66 on Thursday, marking its second consecutive day of losses. The decline occurred during a challenging trading session for the broader market, with the NASDAQ Composite Index falling 0.28% and the Dow Jones Industrial Average falling 0.44%. The stock's performance underperformed the overall market trends.

https://www.marketwatch.com/data-news/tilray-brands-inc-stock-falls-thursday-underperforms-market-85f3afd1-126e4e5d167c?gaa_at=eafs&gaa_n=AWEtsqeQLuC_GdW3dTIfU0_nCDiVhRqUUgV1Qk0bICRs2vrKZcRHVzONGsN9&gaa_ts=69bd3c5b&gaa_sig=kNrMScezVQs9TzYgpeoI73ukjQg2N4P6T2umU3Vs0o43nLJs4_Sz25MWHJvwVmMVFrJuSvGV80AglILstLXsAA%3D%3D

Tilray Medical Expands Medical Cannabis Portfolio in Australia

Tilray Medical has announced its largest-to-date expansion of its medical cannabis portfolio in Australia, introducing new products under its Redecan and Good Supply brands. This expansion, encompassing flower, extracts, vapes, and pastilles, reinforces Tilray Medical's commitment to the Australian market and aims to increase patient access to regulated and clinically supported medical cannabis products. The company sees Australia as a strategic market for its international growth, focusing on quality, genetics, and regulatory compliance.

https://www.cannabisbusinesstimes.com/international/news/15820047/tilray-medical-expands-medical-cannabis-portfolio-in-australia

Trending Today

Mosaic Company (The) ($MOS) Stock Forecast: Down 9.3% Today

QuantumScape Corp. ($QS) Stock Forecast: Down 5.5% Today

FuelCell Energy ($FCEL) Stock Forecast: Down 5.4% Today

Peloton Interactive Inc ($PTON) Stock Forecast: Down 5.7% Today

Kimco Realty Corporation ($KIM) Stock Forecast: Down 3.5% Today

SL Green Realty Corp ($SLG) Stock Forecast: Down 5.2% Today

StoneCo Ltd. ($STNE) Stock Forecast: Down 5.2% Today

Cleveland-Cliffs Inc. ($CLF) Stock Forecast: Down 5.0% Today

American Airlines Group Inc. ($AAL) Stock Forecast: Down 5.4% Today

TKO Group Holdings Inc ($TKO) Stock Forecast: Down 5.2% Today

Tilray Inc. Price History

29.00.2026 - TLRY Stock was down 7.2%

• Tilray's stock plummeted by 3.6% recently due to various reasons:
• Analyst downgrades and missing earnings per share (EPS) figures in the most recent report raised concerns among investors, leading to a decline in stock value.
• The stock's movement below its 50-day and 200-day moving averages signifies a pessimistic market sentiment.
• Despite positive updates about expanding its European medical cannabis platform in Italy, the company encounters obstacles like regulatory challenges, competition from multi-state operators, and high short interest, contributing to its overall underwhelming performance.
• Although the announcement of the SweetWater 420 Fest by Tilray's branch, SweetWater Brewing Company, was positive for the brand, it did not notably impact the stock's trajectory.
• Various analysts' price targets and ratings, for instance, Canaccord Genuity Group's hold rating and a price target of C$13.00, depict a cautious outlook on Tilray's stock performance in the near future.
• Investors keenly observe developments regarding the potential reclassification of U.S. medical cannabis and the company's efficacy in managing losses to evaluate future stock performance amidst previous declines and dilution risks.

10.02.2026 - TLRY Stock was up 6.9%

• TLRY's bullish movement can be attributed to its strategic acquisition of BrewDog's Australian assets, including the Brisbane brewery and a network of bars, to expand its presence in the Asia-Pacific region.
• The expansion into Australia serves as a gateway for Tilray to introduce its broader beverage portfolio to new markets, enhancing its global beverage revenues.
• This move not only strengthens Tilray's international brewing footprint but also positions the company to capitalize on the growing demand for craft beverages in the Asia-Pacific market, driving investor optimism and contributing to the bullish market movement of TLRY.

24.01.2026 - TLRY Stock was up 5.3%

• Despite a new exclusive licensing deal for beer distribution in the U.S. with Carlsberg, Tilray's stock continues to struggle, reflecting ongoing financial difficulties and consistent share price decline.
• The company's active acquisition strategy and continual cash consumption have led to a decrease in shareholder value, prompting analysts to recommend exploring other investment options.
• Despite a slight decrease in Tilray's stock value during a bullish market period, investors are eagerly awaiting the upcoming earnings report, hoping for positive growth in both earnings per share and revenue for the quarter.
• The exclusive U.S. licensing agreement with Carlsberg aims to enhance Tilray's presence in the beverage market but market sentiment remains cautious due to the company's historical performance and limited growth prospects.

20.02.2026 - TLRY Stock was down 5.4%

• Acquired BrewDog's US assets to expand alcohol beverage portfolio did not have a positive impact on stock price.
• Despite expanding medical cannabis portfolio in Australia, introducing new products did not prevent bearish trend.
• Underperformance compared to broader market and sector, along with anticipation of negative earnings per share in upcoming report, likely led to bearish movement.
• Consecutive days of losses amidst challenging trading session for overall market emphasized bearish sentiment surrounding the stock.

22.00.2026 - TLRY Stock was up 5.1%

• TLRY stock experienced a strong bullish movement recently, possibly due to the launch of SweetWater's new high-ABV brew, Big Trip Double IPA, expanding its product offerings to cater to the craft beer market.
• The establishment of Tilray Medical Italia to strengthen its presence in Italy's medical cannabis market might have also played a role in the positive sentiment, demonstrating the company's dedication to increasing its international ventures.
• Despite facing recent share price challenges and analyst downgrades, the company's undervaluation as pointed out by Simply Wall St's analysis could have attracted value investors, contributing to the bullish movement.
• The bullish momentum in TLRY's stock today is thought to be driven by a combination of product expansion in the craft beer sector, strategic endeavors in the medical cannabis market, and potential value opportunities arising from recent price declines.

19.01.2026 - TLRY Stock was up 5.8%

• Tilray's stock experienced a strong bullish movement of over 4% following the announcement of the exclusive brewing and licensing agreement with Carlsberg Group.
• The partnership with Carlsberg is expected to bring immediate scale and revenue to Tilray, driving optimism among investors and leading to the bullish market movement.
• This strategic move aligns with Tilray's focus on partnering with established brands and maximizing its beverage operations, showcasing a promising future for the company in the competitive beer market.
• The market's positive reaction reflects investor confidence in Tilray's ability to leverage its operational infrastructure effectively and strengthen its position in the premium European segment of the US beer market.

05.01.2026 - TLRY Stock was down 6.6%

• The acknowledgment of Tilray Pharma's CC Pharma as a TOP 100 Innovator in Germany underlines the company's dedication to innovation and operational excellence within the pharmaceutical distribution industry.
• Notwithstanding this positive development, the decrease in Tilray Brands shares could be linked to profit-taking by investors following a recent uptrend or broader market uncertainties impacting the stock price.
• The forthcoming nationwide promotional campaign in Tilray's U.S. craft beer taprooms might have shifted investor attention away from the pharmaceutical sector, resulting in a temporary decline in the stock price.
• Investors may be anticipating the upcoming financial update in early April to evaluate the company's overall performance and growth trajectory, possibly influencing the bearish sentiment surrounding the stock today.

28.00.2026 - TLRY Stock was down 5.2%

• Analyst downgrades and a significant earnings per share (EPS) miss contributed to a 3.6% drop in Tilray Brands' shares, leading to the stock trading below its key moving averages.
• Despite some institutional investment interest, the company reported a deeply negative net margin and is projected to have a negative EPS for the current year, impacting investor sentiment.
• The expansion of Tilray's European medical cannabis platform through Italy was seen as a positive move, but investors are still awaiting progress on U.S. medical cannabis reclassification and effective management of losses to mitigate risks.
• The launch of a new high-ABV beer by SweetWater Brewing Company, a subsidiary of Tilray Brands, did not seem to have a significant impact on the stock's bearish movement today.

16.00.2026 - TLRY Stock was down 5.1%

• Tilray's shares declined by 1.9% today, staying close to its 50-day moving average and below its 200-day average, indicating a bearish sentiment in the market.
• The company failed to meet quarterly EPS estimates and revealed negative net margins, resulting in a downgrade to a "strong sell" rating by Zacks Research.
• Despite achieving record Q2 revenues from international operations, Tilray's stock currently holds a Zacks Rank #5 (Strong Sell) primarily due to concerns about its US market prospects.
• Analysts have a cautious stance on Tilray's stock, advising investors to consider other investment opportunities in light of the company's financial performance and market outlook.

05.02.2026 - TLRY Stock was down 5.2%

• The purchase of BrewDog brand and assets may have sparked initial investor interest, but the subsequent stock decline suggests concerns over deal execution or financial impacts.
• Despite expansions in product lines and partnerships, overall market sentiment and uncertainties about the upcoming earnings report likely contributed to TLRY's bearish movement.
• Good Supply's introduction of high-THC products could have provided a small boost, but the limited availability and regional exclusivity may not have been enough to counter broader market pressures.
• TLRY's stock outperformance in the last month despite sector challenges highlights investor scrutiny, particularly with the upcoming earnings report shaping market sentiments.

18.01.2026 - TLRY Stock was up 5.5%

• An analyst has given TLRY a Hold rating and set a price target of C$13, expressing concerns about the beer market and optimism regarding potential US legislation impact.
• Despite falling short of Q4 earnings projections and recording a negative net margin, Zacks Research upgraded its rating on TLRY from "strong sell" to "hold."
• A recent partnership with Smartway Pharmaceuticals to enhance the distribution of medical cannabis products in the UK has been seen as a strategic move that likely boosted investor confidence and contributed to positive stock movement.
• Institutional investors making changes to their holdings by either increasing or starting new positions in TLRY may have helped drive the stock price upwards.

10.01.2026 - TLRY Stock was up 5.2%

• Tilray's stock showed a robust 1.6% bullish movement today, disregarding recent downgrades and cautious analyst views.
• Q2 FY2026 saw the company achieving record net revenue due to growth in international medical cannabis sales and Canadian adult-use cannabis. This demonstrates its ability to navigate market fluctuations.
• The company's expansion of its U.S. beverage alcohol division and recognition of its German medical distribution subsidiary showcase strategic efforts to diversify revenue sources and bolster presence in key markets.
• Notwithstanding challenges like missed earnings estimates and negative net margin, Tilray's dual focus on medical cannabis and spirits sectors, along with international expansion, appears to have positively impacted investor sentiment and influenced today's bullish movement.